Company Growth (employees)
Orexigen Therapeutics was founded in 2002 and is headquartered in San Diego, US
Orexigen Therapeutics Office Locations
Orexigen Therapeutics has an office in San Diego
San Diego, US (HQ)
200 3344 N Torrey Pines Ct
Orexigen Therapeutics Data and Metrics
Orexigen Therapeutics Financial Metrics
Orexigen Therapeutics's revenue was reported to be $33.7 m in FY, 2016 which is a 38% increase from the previous period.
USD
Revenue (FY, 2016) | 33.7 m |
Revenue growth (FY, 2015 - FY, 2016), % | 38% |
Gross profit (FY, 2016) | 25.7 m |
Gross profit margin (FY, 2016), % | 76% |
Net income (FY, 2016) | (24.5 m) |
EBIT (FY, 2016) | (57 m) |
Market capitalization (21-Jul-2017) | 38.9 m |
Cash (31-Dec-2016) | 92.5 m |
Orexigen Therapeutics's current market capitalization is $38.9 m.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 3.4 m | 55.5 m | 24.5 m | 33.7 m |
Revenue growth, % | 1520% | (56%) | 38% | |
Cost of goods sold | 8 m | |||
Gross profit | 25.7 m | |||
Gross profit Margin, % | 76% | |||
R&D expense | 38 m | |||
General and administrative expense | 118.6 m | |||
Operating expense total | 80.6 m | 86.1 m | 84.5 m | 82.7 m |
EBIT | (77.2 m) | (30.5 m) | (60.1 m) | (57 m) |
EBIT margin, % | (2252%) | (55%) | (246%) | (169%) |
Interest expense | 538 k | 7.1 m | 7.4 m | (7.9 m) |
Interest income | 65 k | 88 k | 227 k | 622 k |
Pre tax profit | (67.3 m) | (24.4 m) | ||
Income tax expense | (1.4 m) | (133 k) | ||
Net Income | (77.7 m) | (37.5 m) | (68.7 m) | (24.5 m) |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 98.1 m | 104.2 m | 155.4 m | 92.5 m |
Accounts Receivable | 2.6 m | 6.8 m | 1.1 m | |
Inventories | 1.3 m | 1.5 m | 2.3 m | 23.2 m |
Current Assets | 178.3 m | 211.3 m | 233.9 m | 224.5 m |
PP&E | 630 k | 857 k | 1.3 m | 1 m |
Total Assets | 180.1 m | 213 m | 236.6 m | 304.6 m |
Accounts Payable | 4.8 m | 4.2 m | 6.5 m | 15.2 m |
Current Liabilities | 22.9 m | 29.7 m | 32.2 m | 65.4 m |
Additional Paid-in Capital | 556.2 m | 574.2 m | 653.7 m | 698.2 m |
Retained Earnings | (514.5 m) | (552 m) | (620.7 m) | (645.2 m) |
Total Equity | 41.9 m | 22.3 m | 33.4 m | 57 m |
Financial Leverage | 4.3 x | 9.5 x | 7.1 x | 5.3 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (77.7 m) | (37.5 m) | (68.7 m) | (24.5 m) |
Depreciation and Amortization | 94 k | 139 k | 223 k | 3.7 m |
Accounts Receivable | (2.5 m) | (4.3 m) | 5.7 m | |
Inventories | 205 k | (175 k) | (781 k) | 1.5 m |
Accounts Payable | (2.3 m) | 2.1 m | 1 m | 11.8 m |
Cash From Operating Activities | (70.8 m) | 6.1 m | 51.2 m | |
Purchases of PP&E | (640 k) | (246 k) | (538 k) | (330 k) |
Cash From Investing Activities | (21.3 m) | (23.4 m) | 41.4 m | (107.1 m) |
Long-term Borrowings | (10 m) | |||
Cash From Financing Activities | 111.9 m | 2.7 m | 64.3 m | 154.6 m |
Interest Paid | 3.1 m | 3.2 m | 3.2 m | |
Income Taxes Paid | 28 k | 1.3 m |
| USD | Y, 2016 |
|---|---|
Revenue/Employee | 503.1 k |
Financial Leverage | 5.3 x |
